Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: A prospective, randomized, open-label, blinded end-point trial

Clinical Therapeutics

Volumn 30, Issue 1, 2008, Pages 108-120

  Hermida, Ramón C ^a   Ayala, Diana E ^a   Khder, Yasser ^b   Calvo, Carlos ^c  

^a UNIVERSITY OF VIGO   (Spain)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

Author keywords

ambulatory blood pressure monitoring; circadian rhythm; clinicaltrials.gov identifier: NCT00302705.; enalapril; missed dose; treatment efficacy; valsartan

Indexed keywords

ENALAPRIL; VALSARTAN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSED DRUG DOSE; MORNING DOSAGE; OPEN STUDY; PATIENT COMPLIANCE; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SPAIN;

ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CHOLESTEROL; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TETRAZOLES; URIC ACID; VALINE;

EID: 45149087687     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.01.012     Document Type: Article

References (40)

1. Muller J., Stone P., and Turi Z. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 313 (1985) 1315-1322
2. Muller J., Ludmer P., and Willich S. Circadian variation in the frequency of sudden cardiac death. Circulation 75 (1987) 131-138
3. Cohen M., Rohtla K., and Lavery C. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death [published correction appears in Am J Cardiol. 1998;81:260]. Am J Cardiol 79 (1997) 1512-1516
4. Manfredini R., Boari B., and Smolensky M. Circadian variation in stoke onset: Identical temporal patterns in ischemic and hemorrhagic events. Chronobiol Int 22 (2005) 417-453
5. Millar-Craig M., Bishop C., and Raftery E. Circadian variation of blood-pressure. Lancet 1 (1978) 795-797
6. Hermida R., Ayala D., and Fernández J. Modeling the circadian variability of ambulatorily monitored blood pressure by multiple-component analysis. Chronobiol Int 19 (2002) 461-481
7. Portaluppi F., and Smolensky M. Circadian rhythm and environmental determinants of 24-hour blood pressure regulation in normal and hypertensive conditions. In: White W. (Ed). Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. 2 (2007), Humana Press, Totowa, NJ 135-158
8. Chobanian A., Bakris G., Black H., for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; the National Heart, Lung, and and Blood Institute; and the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
9. Mancia G., De Backer G., Dominiczak A., and for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [published correction appears in J Hypertens. 2007;25:1749]. J Hypertens 25 (2007) 1105-1187
10. Markham A., and Goa K. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 54 (1997) 299-311
11. Neutel J., Weber M., and Pool J. Valsartan, a new angiotensin II antagonist: Antihypertensive effects over 24 hours. Clin Ther 19 (1997) 447-458 discussion 367-368
12. Himmelmann A., Keinänen-Kiukaanniemi S., and Wester A. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press 10 (2001) 43-51
13. Barnett A., Bain S., Bouter P., and for the Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [published correction appears in N Engl J Med. 2005;352:1731]. N Engl J Med 351 (2004) 1952-1961
14. Nissen S., Tuzcu E., and Libby P. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT Study: A randomized controlled trial. JAMA 292 (2004) 2217-2225
15. Kasama S., Toyama T., and Hatori T. Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure. Heart 92 (2006) 625-630
16. Turnbull F., Neal B., and Pfeffer M. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25 (2007) 951-958
17. O'Brien E., Asmar R., and Beilin L. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 21 (2003) 821-848
18. Pickering T., Hall J., Appel L., and for the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 45 (2005) 142-161
19. Anwar Y., Giacco S., and McCabe E. Evaluation of the efficacy of the Omron HEM-737 IntelliSense device for use on adults according to the recommendations of the Association for the Advancement of Medical Instrumentation. Blood Press Monit 3 (1998) 261-265
20. O'Brien E., Sheridan J., and O'Malley K. Dippers and non-dippers. Lancet 2 (1988) 397 Letter
21. Mansoor G., White W., McCabe E., and Giacco S. The relationship of electronically monitored physical activity to blood pressure, heart rate, and the circadian blood pressure profile. Am J Hypertens 13 (2000) 262-267
22. Hermida R., Calvo C., and Ayala D. Relationship between physical activity and blood pressure in dipper and non-dipper hypertensive patients. J Hypertens 20 (2002) 1097-1104
23. Hermida R., Calvo C., and Ayala D. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 42 (2003) 283-290
24. Hermida R., Calvo C., and Ayala D. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens 23 (2005) 1913-1922
25. Hermida R., Calvo C., Ayala D., and López J. Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 46 (2005) 960-968
26. Hermida R., Calvo C., and Ayala D. Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. Chronobiol Int 22 (2005) 755-776
27. Staessen J., Fagard R., and Lijnen P. Ambulatory blood pressure monitoring in clinical trials. J Hypertens Suppl 9 (1991) S13-S19
28. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 6 (1979) 65-70
29. Hermida R., and Smolensky M. Chronotherapy of hypertension. Curr Opin Nephrol Hypertens 13 (2004) 501-505
30. Hermida R., Ayala D., and Calvo C. Administration-time-dependent effects of antihypertensive treatment on the circadian pattern of blood pressure. Curr Opin Nephrol Hypertens 14 (2005) 453-459
31. Kario K., Pickering T., and Umeda Y. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study. Circulation 107 (2003) 1401-1406
32. Verdecchia P., Porcellati C., and Schillaci G. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension [published correction appears in Hypertension. 1995;25:462]. Hypertension 24 (1994) 793-801
33. Staessen J., Thijs L., Fagard R., and for the Systolic Hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 282 (1999) 539-546
34. Ohkubo T., Hozawa A., Yamaguchi J., et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J Hypertens 20 (2002) 2183-2189
35. Kikuya M., Ohkubo T., Asayama K., et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: The Ohasama study. Hypertension 45 (2005) 240-245
36. Dolan E., Stanton A., Thijs L., et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: The Dublin outcome study. Hypertension 46 (2005) 156-161
37. Yusuf S., Sleight P., Pogue J., et al., for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published corrections appear in N Engl J Med. 2000;342:1376 and N Engl J Med. 2000;342:748]. N Engl J Med 342 (2000) 145-153
38. Svensson P., de Faire U., Sleight P., et al. Comparative effects of ramipril on ambulatory and office blood pressures: A HOPE Substudy. Hypertension 38 (2001) E28-E32
39. Hansson L., Hedner T., and Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press 1 (1992) 113-119
40. Smith D., Neutel J., Lacourciére Y., and Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens 21 (2003) 1291-1298